Verici Dx plc (AIM:VRCI)
0.4000
+0.0250 (6.67%)
Jun 17, 2026, 3:37 PM GMT
Verici Dx Revenue
Verici Dx had revenue of $1.91M USD in the half year ending June 30, 2025, with 9,968.42% growth. This brings the company's revenue in the last twelve months to $1.91M, down -55.85% year-over-year. In the year 2024, Verici Dx had annual revenue of $3.34M with 229.62% growth.
Revenue (ttm)
$1.91M
Revenue Growth
-55.85%
P/S Ratio
4.06
Revenue / Employee
$127.53K
Employees
15
Market Cap
5.68M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.34M | 2.33M | 229.62% |
| Dec 31, 2023 | 1.01M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 45.77B |
| GSK plc | 32.78B |
| Haleon | 11.03B |
| Smith & Nephew | 4.58B |
| Proteome Sciences | 3.76M |
| GENinCode | 3.08M |
| OptiBiotix Health | 1.17M |
| CRISM Therapeutics | 25.00K |
Verici Dx News
- 4 weeks ago - CORRECTING and REPLACING Verici Dx Announces Publication Validating Pre-Transplant Gene Signature Test for Predicting Early Acute Rejection in Kidney Transplant Recipients - Business Wire
- 4 weeks ago - Verici Dx Announces Publication Validating Pre-Transplant Gene Signature Test for Predicting Early Acute Rejection in Kidney Transplant Recipients - Business Wire
- 2 months ago - Verici Dx Earnings release: Q1 2026 - Filings
- 4 months ago - Verici Dx Earnings release: H2 2025 - Filings
- 9 months ago - Verici Dx Earnings Call Transcript: H1 2025 - Transcripts
- 9 months ago - Verici Dx Quarterly report: H1 2025 - Filings
- 9 months ago - Verici Dx Slides: H1 2025 - Filings
- 1 year ago - Verici Dx Annual report: H2 2024 - Filings